

## QIBA Executive Committee (EC) Conference-Call Meeting

Thursday, January 23, 2020

10:00 AM (CT)

Draft Call Summary

### Participants:

Daniel Sullivan, MD (*QIBA Chair*)

Alex Guimaraes, MD, PhD (*QIBA Vice Chair*)

Tim Hall, PhD (*QIBA Vice Chair*)

Michael Boss, PhD

Rudresh Jarecha, MBBS

David Mozley, MD

Robert Nordstrom, PhD

Kevin O'Donnell, MASc

Nancy Obuchowski, PhD

Gudrun Zahlmann, PhD

### RSNA Staff:

Angela Colmone, PhD

Fiona Miller

Joe Koudelik

Tori Peoples

Dr. Sullivan announced that the summary of the October 10<sup>th</sup> (2019) EC call will be distributed with the summary of the January 23<sup>rd</sup> EC call.

### Draft Agenda for the QIBA 2020 Annual Meeting

Dr. Sullivan indicated that the focus of the meeting will be on some of the processes and challenges that affect all BCs. He reviewed the draft agenda indicating that the SC portion of the meeting was subject to change in efforts to reduce topic duplication. Since the Process and SIG Committees also report out in the general session, it might be possible to use some of that time for other purposes, e.g. expand CC reports, the ongoing MITA discussions, or to discuss greater AAPM collaboration (by inviting the AAPM Chair). One suggestion was to collaborate on the development of a phantom library. It was suggested that Dr. Stephen Russek (NIST), Mr. Zach Hornberger (MITA), and an IEC rep could be invited to be part of the phantom discussion. Additional suggestions to be made by Mr. O'Donnell or Dr. Carson, e.g., Dr. Michael Steckner. Dr. Boss suggested that Dr. Tromberg (NIBIB) might be invited to the SC. Dr. Sullivan said consideration will be given to the balance of speakers and time for group discussion.

For the general session, the desire is to have more discussion and shorter didactic sessions. Proposed topics include:

- Plenary Session 1: Reassessing Profile structure (improving brevity, checklists, etc.) - Invite feedback from various stakeholders including imaging sites, core labs, and industry partners. What is needed to get stakeholders to adopt. Dr. Boss suggested addressing the difficulty of getting Profiles past Technically Confirmed (Stage 3), e.g., what are common hurdles faced when moving past Stage3?
- Plenary Session 2: Information dissemination (publications/marketing) - Our accomplishments are not widely known to people outside of QIBA. The medical community needs a better understanding regarding the value of QIBA. What questions do stakeholders need answered to implement Profile use?
- Plenary Session 3: Research grants (PCF, SBIR, NIH, etc.) - It was suggested to broaden this topic and ask each of the BCs/CCs to identify what groundwork is needed to move Profiles forward, and to

identify a possible source of funding. Interest in hearing the NCI perspective (Dr. Shankar), or NCTN and cooperative groups regarding Profile adoption into clinical trials suggested. Inviting one cooperative group (oncology) chair suggested, such as Dr. Monica Bertignolli (head of oncology at ECOG-ACRIN), or Dr. Peter O'Dwyer (ECOG-ACRIN). "Seeding adoption" and lesson learned from the ongoing success of J-QIBA's suggested.

- Plenary Session 4: Conformance and Accreditation (and other sustainability implementation efforts) – Suggested panelists included Dr. Jacob Hesterman, Senior VP of Image Analysis at inviCRO (an iCRO collaborating with QIBA assessing the DWI self-attestation conformance process. Also, opportunity for Dr. Eliot Siegel (RadSite) to share his views from an accreditation organization. In addition, Dr. Ronald Boellaard was suggested as the SC rep from EANM (if accreditation progress has been made in the FDG/NM area).

### **Process Committee Update - October 15<sup>th</sup> Change Proposal Version**

Mr. O'Donnell presented a change proposal regarding the updated EC charter. The essence of the proposal was to explain how the EC can streamline the workload of the SC. The smaller, nimbler EC will perform mostly administrative duties with limited voting authority, allowing the SC more time for strategic planning. The SC remains the overarching authority but does delegate limited power to the EC for non-controversial issues. EC votes do not require SC ratification, but the SC may ask questions and/or reverse EC votes. The EC to bring high-level issues to the SC for discussion and resolution. SC members are welcome to attend EC calls as guests.

Dr. Hall moved to approve the charter as presented. Hearing no objections, the motion carried unanimously.

### **QIBA Leadership Structure Update**

Dr. Sullivan explained the leadership changes following Dr. Jackson stepping down. Among the three leaders, Dr. Sullivan has assumed the role of QIBA Chair through RSNA 2020, with Drs. Guimaraes and Hall acting as Vice-chairs. Dr. Sullivan will be succeeded by Dr. Guimaraes and then Dr. Hall (staggered rotations). When Dr. Sullivan steps down, a replacement Vice-chair will be appointed.

If anyone wishes to send a card to Dr. Jackson, they can be sent to the attention of Dr. Hall at U Wisconsin.

### **Sustainability Implementation Group (SIG) Update**

Dr. Zahlmann provided a brief overview of activities to date. The SIG is developing a strategy re certification services roll-out, but champions are needed to direct communications. Drs. Boss and Chenevert are already working in this capacity guiding the DWI Profile Conformance process and developing new collaborations. Dr. Zahlmann noted that a champion from both the CT CC and NM CC are still needed for the RadSite Pilot efforts.

Slides will be shared with EC members.

**Multiparametric Metrology Workgroup Update (Dr. Obuchowski);** Discussion deferred to next call

**QIN Update (Dr. Nordstrom);** Discussion deferred to next call

**Next QIBA EC T-con Meeting: Thursday, February 20, 2020 @ 10:00AM (CT)**